Monoamine oxidase and α-synuclein as targets in Parkinson's disease therapy (Q38213838)

31 August 2017

Monoamine oxidase and α-synuclein as targets in Parkinson's disease therapy (English)

1 reference

31 August 2017

1 reference

1 reference

Cristian Follmer

1

1 reference

31 August 2017

1 June 2014

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

31 August 2017

1 reference

31 August 2017

14

1 reference

31 August 2017

6

1 reference

31 August 2017

703-716

1 reference

The Parkinson's complex: parkinsonism is just the tip of the iceberg

31 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Peripheral markers of oxidative stress in Parkinson's disease. The role of L-DOPA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Plasma and CSF markers of oxidative stress are increased in Parkinson's disease and influenced by antiparkinsonian medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Dopaminergic therapy promotes lateralized motor activity in the subthalamic area in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

The therapeutic potential of monoamine oxidase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Some observations upon a new inhibitor of monoamine oxidase in brain tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

The effect of deprenyl and levodopa on the progression of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Alpha-synuclein in Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Widespread occurrence of alpha-synuclein/NACP-immunoreactive neuronal inclusions in juvenile and adult-onset Hallervorden-Spatz disease with Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Alpha-Synuclein aggregation in pathological aging and Alzheimer's disease: the impact of beta-amyloid plaque level.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson's disease pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

JNK signaling pathway is a key modulator in cell death mediated by reactive oxygen and nitrogen species

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Brain iron and ferritin in Parkinson's and Alzheimer's diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Oxidation of 3,4-dihydroxyphenylacetaldehyde, a toxic dopaminergic metabolite, to a semiquinone radical and an ortho-quinone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

ALDH1 mRNA: presence in human dopamine neurons and decreases in substantia nigra in Parkinson's disease and in the ventral tegmental area in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Metabolic stress in PC12 cells induces the formation of the endogenous dopaminergic neurotoxin, 3,4-dihydroxyphenylacetaldehyde

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Accumulation of 3,4-dihydroxyphenylglycolaldehyde, the neurotoxic monoamine oxidase A metabolite of norepinephrine, in locus ceruleus cell bodies in Alzheimer's disease: mechanism of neuron death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Comparative platelet proteome analysis reveals an increase of monoamine oxidase-B protein expression in Alzheimer's disease but not in non-demented Parkinson's disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease: possible implications of glial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Monoamine oxidase inhibitor update. Potential adverse food and drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Limited potentiation of blood pressure response to oral tyramine by brain-selective monoamine oxidase A-B inhibitor, TV-3326 in conscious rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Monoamine oxidase-dependent metabolism of dopamine in the striatum and substantia nigra of L-DOPA-treated monkeys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Prospective study of cigarette smoking and the risk of developing idiopathic Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Inhibition of monoamine oxidase B in the brains of smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Gene-environment interplay in alcoholism and other substance abuse disorders: expressions of heritability and factors influencing vulnerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Human monoamine oxidase is inhibited by tobacco smoke: beta-carboline alkaloids act as potent and reversible inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

The beta-carbolines (harmanes) - a new class of endogenous compounds: their relevance for the pathogenesis and treatment of psychiatric and neurological diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

beta-Carboline alkaloids: biochemical and pharmacological functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Human monoamine oxidase enzyme inhibition by coffee and beta-carbolines norharman and harman isolated from coffee

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Association of coffee and caffeine intake with the risk of Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Isolation and characterization of a monoamine oxidase inhibitor from tobacco leaves

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Neuroprotection in the MPTP Parkinsonian C57BL/6 mouse model by a compound isolated from tobacco

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

21 January 2018

Flavonoids and the CNS.

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Dietary inhibitors of monoamine oxidase A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Curcumin reverses impaired cognition and neuronal plasticity induced by chronic stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Inhibition of monoamine oxidase-B by the polyphenolic compound, curcumin and its metabolite tetrahydrocurcumin, in a model of Parkinson's disease induced by MPTP neurodegeneration in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

REVIEW: Curcumin and Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

The aggregation and fibrillation of alpha-synuclein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Mutation in the alpha-synuclein gene identified in families with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

α-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

α-Synuclein as an intrinsically disordered monomer--fact or artefact?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Properties of native brain α-synuclein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Phosphorylation of tau and alpha-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer's disease, and in Parkinson's disease and related alpha-synucleinopathies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Neurodegenerative disease: amyloid pores from pathogenic mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

In vivo demonstration that alpha-synuclein oligomers are toxic

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease models

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

A Drosophila model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Conversion of wild-type alpha-synuclein into mutant-type fibrils and its propagation in the presence of A30P mutant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

The physical basis of how prion conformations determine strain phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Systematic mutagenesis of α-synuclein reveals distinct sequence requirements for physiological and pathological activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Formation of dopamine-mediated alpha-synuclein-soluble oligomers requires methionine oxidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Dopamine-mediated oxidation of methionine 127 in α-synuclein causes cytotoxicity and oligomerization of α-synuclein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Anti-Parkinsonian agents have anti-amyloidogenic activity for Alzheimer's beta-amyloid fibrils in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Anti-fibrillogenic and fibril-destabilizing activities of anti-Parkinsonian agents for alpha-synuclein fibrils in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Entacapone and tolcapone, two catechol O-methyltransferase inhibitors, block fibril formation of alpha-synuclein and beta-amyloid and protect against amyloid-induced toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

The flavonoid baicalein inhibits fibrillation of alpha-synuclein and disaggregates existing fibrils

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Inhibition of alpha-synuclein fibrillization by dopamine analogs via reaction with the amino groups of alpha-synuclein. Implication for dopaminergic neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Curcumin prevents aggregation in α-synuclein by increasing reconfiguration rate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Curcumin inhibits aggregation of alpha-synuclein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Curcumin reduces alpha-synuclein induced cytotoxicity in Parkinson's disease cell model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Monoamine oxidase B (MAO-B) inhibition by active principles from Uncaria rhynchophylla

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

A novel conjugated agent between dopamine and an A2A adenosine receptor antagonist as a potential anti-Parkinson multitarget approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Restoration of nigrostriatal dopamine neurons in post-MPTP treatment by the novel multifunctional brain-permeable iron chelator-monoamine oxidase inhibitor drug, M30.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Multi target neuroprotective and neurorestorative anti-Parkinson and anti-Alzheimer drugs ladostigil and m30 derived from rasagiline

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Substrate and inhibitor specificities for human monoamine oxidase A and B are influenced by a single amino acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Monoamine oxidase inhibitory components from Cayratia japonica.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

The Anti-Parkinsonian Drug Selegiline Delays the Nucleation Phase of α-Synuclein Aggregation Leading to the Formation of Nontoxic Species

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

α-Synuclein facilitates the toxicity of oxidized catechol metabolites: Implications for selective neurodegeneration in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Dopamine Affects the Stability, Hydration, and Packing of Protofibrils and Fibrils of the Wild Type and Variants of α-Synuclein†

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Vitamins K interact with N-terminus α-synuclein and modulate the protein fibrillization in vitro. Exploring the interaction between quinones and α-synuclein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

Aldehyde dehydrogenase 2 in sporadic Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.920235

10.1586/14737175.2014.920235

21 January 2018

Identifiers

DOI

1 reference

31 August 2017

1 reference

PubMed ID

24852232